New Technology– category –
-
FDA Streamlines Nonclinical Studies for Biologics and Conjugated Products, Accepting NAMs for ADCs to Reduce Non-Human Primate Use
FDA USA Overview The FDA's Center for Drug Evaluation and Research (CDER) is streamlining nonclinical studies for biologics and conjugated products, including Antibody-Drug Conjugates (ADCs) and CD3 bispecific T-cell engagers. For ADCs w... -
Imperial College London’s DeCAF-Pearl AI Model Enables Practical Large-Scale Molecular Screening, Surpassing AlphaFold 3 Efficiency
Imperial College London UK Overview Researchers at Imperial College London, in collaboration with the Genesis Research Team, have developed DeCAF-Pearl, a new AI model based on flow maps that makes large-scale molecular screening practic... -
UVA’s YuelDesign AI Framework Models Protein Flexibility for Improved Drug Design, Demonstrating Success on CDK2 Target
IntuitionLabs USA Overview The YuelDesign framework, developed by a UVA team, represents a significant advancement in structure-based drug design by explicitly modeling protein flexibility during ligand generation using AI diffusion mode... -
Latent Labs’ Generative AI Transforms Molecular Design, Producing Macrocyclic Peptides and Antibody Candidates in Weeks
CVPR (Computer Vision and Pattern Recognition) USA Overview Latent Labs, through its Latent-X1 and Latent-Y platforms, is transforming drug discovery by enabling de novo molecular design from intent, rather than traditional library scree... -
ThinkBio.Ai Leads AI Drug Discovery Tools Market, Innovating Target Identification and Clinical Trial Planning
BioStock Info スウェーデン Overview AI is generating significant value across drug discovery by enhancing target identification, drug repurposing, and clinical trial planning. Platforms like ThinkBio.Ai, Schrödinger, and Insilico Medicin... -
Isomorphic Labs Advances AI-Designed Oncology and Immunology Therapeutics to Clinical Trials Leveraging AlphaFold 3
IntuitionLabs UK Overview Isomorphic Labs is advancing its first computationally designed oncology and immunology therapeutics into clinical trials, leveraging AlphaFold-derived AI models, including AlphaFold 3. The company aims to drast... -
Protai Introduces Structural-Proteomics-Guided AI ‘AIMS-Fold’ to Revolutionize Induced Proximity Drug Design
BioSpace USA Overview Protai announced two preprints introducing AIMS-Fold, a structural-proteomics-guided generative AI framework for protein complex modeling, specifically for induced proximity therapeutics like PROTACs and molecular g... -
MDPI Highlights AI Drug Discovery’s Clinical Impact Deficit and Validation Crisis: AlphaFold’s Limitations and Regulatory Challenges
MDPI Switzerland Overview A review article by MDPI discusses the current state of AI in drug discovery (2022-2026), noting significant investment and accelerated early-stage discovery timelines but highlighting limited validated clinical... -
bioRxiv: APOSM Improves Generative Small-Molecule Design via Pairwise Preference Learning, Accelerating Lead Optimization
bioRxiv USA Overview A bioRxiv preprint introduces APOSM, an active-learning algorithm that enhances generative small-molecule design by employing pairwise preference learning for surrogate models, moving beyond absolute scores. This met... -
AI/Machine Learning Drives Target Identification and Precision Nanomedicine in Drug Discovery, Enhancing Candidate Selection and Pathway Analysis
Dove Medical Press USA Overview Machine learning (ML) and deep learning (DL) strategies are advancing drug discovery by enhancing target identification and precision nanomedicine. These technologies leverage virtual screening and bioacti...
